Avidity Biosciences
RNA
RNA
195 hedge funds and large institutions have $4.57B invested in Avidity Biosciences in 2024 Q2 according to their latest regulatory filings, with 57 funds opening new positions, 74 increasing their positions, 49 reducing their positions, and 18 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
195
Holders Change
+37
Holders Change %
+23.42%
% of All Funds
2.84%
Holding in Top 10
9
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+28.57%
% of All Funds
0.13%
New
57
Increased
74
Reduced
49
Closed
18
Calls
$7.63M
Puts
$11.2M
Net Calls
-$3.61M
Net Calls Change
-$4.93M
Top Buyers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$142M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$105M |
| 3 |
BlackRock
New York
|
+$100M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$98.7M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$86.5M |
Top Sellers
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$24.6M |
| 2 |
CAC
Cowen and Company
New York
|
-$20.4M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$17.3M |
| 4 |
5VM
5AM Venture Management
San Francisco,
California
|
-$17M |
| 5 |
JPMorgan Chase & Co
New York
|
-$16.8M |
